Trials / Terminated
TerminatedNCT00522808
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Arrow Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are: * to determine the safety and tolerability of multiple doses of A-831 at various doses * to determine how multiple doses of A-831 are distributed through the bloodstream * to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A-831 |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-03-01
- Completion
- 2008-05-01
- First posted
- 2007-08-30
- Last updated
- 2008-09-29
Locations
3 sites across 2 countries: New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT00522808. Inclusion in this directory is not an endorsement.